Suyash Prasad

Suyash Prasad is a physician-scientist and executive leader in the field of gene therapy with over 15 years of experience in the biotech and pharmaceutical industry. Suyash is currently the Executive Clinical Advisor at Chameleon Biosciences, a position they have held for 2 years and 1 month. Prior to this, they served as the Chief Medical Officer and Head of Research and Development at Taysha Gene Therapies, where they oversaw the development of multiple AAV gene therapy candidates targeting severe neurological diseases. Suyash has also served as a Principal at Suyash Prasad Consulting LLC, where they provided consulting services to venture capital investors, small start-up biotechs, and patient organizations in the gene therapy, genetic medicines, and rare disease space. In addition, they have served as the Chief Medical Officer and Senior Vice President at Audentes Therapeutics and as the Senior Group Medical Director, Development Sciences at BioMarin Pharmaceuticals. Dr. Prasad received their medical degree from Eli Lilly in the UK and has since dedicated their career to developing innovative treatments for patients with rare diseases.

Suyash Prasad has an MBBS from the University of Newcastle-upon-Tyne, UK, and MRCP and MRCPCH qualifications from the Royal College of Physicians. Suyash also has a Postgraduate Diploma in Pharmaceutical Medicine from the University of Wales, Cardiff, and an MFPM qualification from the Royal College of Physicians. Suyash has a Certificate of Completion of Training in Pharmaceutical Medicine from the Royal College of Physicians, and a Masters in Translational Science from Kings College London.